Work

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma

Year: 2021

Type: article

Abstract: GAs on the activity of EV and the optimal sequencing of EV and erdafitinib in mUC.

Source: BJUI Compass

DOI: 10.1002/bco2.125

Authors: Elio Adib, Talal El‐Zarif, Rohit K. Jain, William P. Skelton, Dory Freeman, Catherine Curran, Elie W. Akl, Amin H. Nassar, Praful Ravi, Charlene Mantia, David J. Kwiatkowski, Toni K. Choueiri, Guru P. Sonpavde

Institutions: Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Moffitt Cancer Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,400

Funders: National Institutes of Health, National Cancer Institute

Awards: G4898130671, Integrative molecular dissection of acquired resistance to PD1/PD-L1 blockade in localized and metastatic urothelial carcinoma

OpenAlex ID: W3214509657

FWCI: 1.899

Cites: 9

Cited by: 16

Related to: 10